Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion

NCT04234048 is registered in ClinicalTrials.gov with SciTech Development, Inc. as lead sponsor.

NCT NCT04234048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04234048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Trial in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma to Determine the Safety Profile, Pharmacology, and Maximum Tolerated Dose of ST-001, a Fenretinide Phospholipid Suspension (12.5 mg/mL) for Intravenous Infusion
Lead sponsor
SciTech Development, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 18, 2023
Completion date
November 1, 2028
Enrollment
46 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

angioimmunoblastic t-cell lymphoma, cutaneous t-cell lymphoma, cutaneous t-cell lymphoma, unspecified, cutaneous/peripheral t-cell lymphoma, follicular t-cell lymphoma, mycosis fungoides, peripheral t-cell lymphoma, peripheral t-cell lymphoma, not classified, primary cutaneous t-cell lymphoma, sézary's disease, t-cell lymphoma